Technology ID
E-158-2013-3

Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine

Linked ID
TAB-2621
Inventors
Conrad Quinn (CDC)
Jan Pohl (CDC)
Jarad Schiffer (CDC)
Pavel Svoboda (CDC)
Shannon Dalton (CDC)
Stephen Soroka (CDC)
Vera Semenova (CDC)
Lead Inventors
Vera Semenova (CDC)
Co-Inventors
Conrad Quinn (CDC)
Jan Pohl (CDC)
Jarad Schiffer (CDC)
Pavel Svoboda (CDC)
Shannon Dalton (CDC)
Stephen Soroka (CDC)
Development Status
  • Pre-clinical
  • In vitro data available
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
ICs
CDC
Commercial Applications
  • Novel anthrax vaccines
  • Post-vaccination screening to determine if anthrax protection is achieved
  • Biodefense
Bacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection is achieved. Specifically, this invention relates to a screening method for determining protection against B. anthracis infection that involves testing a biological sample for the presence of antibodies to one or more predefined regions of B. anthracis PA. This technology may be important to any bioterrorism defense strategy.
Competitive Advantages
  • May require fewer vaccination follow-ups, while present anthrax vaccines require numerous rounds of injections and boosters for full-effectiveness.
  • Identified peptide sequences, representing regions of PA, elicit an immune response in primate and human sera studies.

Request More Info

Licensing Contact